Philip Agop Philip

Philip Agop Philip's AcademicInfluence.com Rankings

Philip Agop Philip

Philosophy

#8292

World Rank

#11644

Historical Rank

Logic

#5330

World Rank

#6721

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Philip Agop Philip's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Philip Agop Philip Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philip Agop Philip's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial (2018) (1140)
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. (2009) (654)
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) (649)
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. (2010) (579)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. (2017) (443)
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. (2005) (443)
miR-146a suppresses invasion of pancreatic cancer cells. (2010) (428)
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. (2010) (417)
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. (2005) (383)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. (2016) (353)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. (2019) (308)
Phase II study of erlotinib in patients with advanced biliary cancer. (2006) (300)
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. (2010) (244)
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (241)
A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma (2006) (238)
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. (2009) (231)
Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer (2010) (230)
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. (2005) (225)
Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer (2011) (207)
Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study (2007) (205)
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. (2018) (187)
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. (2004) (184)
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. (2010) (168)
Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. (2013) (159)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. (2019) (155)
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo (1993) (153)
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma (2013) (152)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. (2013) (152)
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. (2008) (150)
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers (2018) (144)
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma (2001) (142)
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. (2004) (140)
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers (2017) (135)
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). (2020) (129)
Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BxPC-3 Pancreatic Cancer Cell Line (2004) (128)
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial (2017) (126)
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer (2012) (123)
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. (2006) (118)
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. (2013) (114)
Exploitation of protein kinase C: a useful target for cancer therapy. (2009) (113)
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. (2020) (113)
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy (2013) (108)
Emerging Bcl-2 inhibitors for the treatment of cancer (2011) (103)
Metastatic Pancreatic Cancer: ASCO Guideline Update. (2020) (102)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. (2016) (101)
Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. (2012) (101)
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. (2018) (100)
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. (2010) (98)
Surgical Outcome Results From SWOG S1505 (2020) (98)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. (2021) (97)
Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations (2010) (97)
A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer (2005) (94)
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. (2004) (91)
The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. (2016) (91)
Structure-Activity Studies on Therapeutic Potential of Thymoquinone Analogs in Pancreatic Cancer (2010) (86)
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. (2021) (85)
Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer (2006) (85)
Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and Its Relationship to Pathologic and Clinical Parameters (2001) (84)
Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. (2014) (83)
Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer (2008) (83)
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. (2001) (82)
MicroRNA and Cancer: Tiny Molecules with Major Implications (2008) (82)
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727) (2014) (81)
Inactivation of NF-κB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells (2007) (77)
Vascular endothelial growth factor in the management of hepatocellular carcinoma (2009) (74)
Cytochrome p450 and glutathione transferase expression in human breast cancer. (2003) (71)
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer (2012) (70)
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy (2005) (70)
Male fertility preservation and cancer treatment. (2004) (68)
Metabolomics in cancer: a bench-to-bedside intersection. (2012) (68)
Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy (2013) (68)
Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. (2015) (68)
Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer (2003) (66)
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. (2009) (63)
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma (2016) (63)
Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines (2009) (62)
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. (2010) (61)
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. (2016) (60)
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma (2012) (59)
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. (1992) (58)
A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. (2006) (58)
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. (1993) (58)
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. (1992) (58)
Expression of microRNAs: potential molecular link between obesity, diabetes and cancer (2011) (58)
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K‐Ras transgenic mouse model of pancreatic cancer (2012) (57)
Acetylator status and its relationship to breast cancer and other diseases of the breast. (1987) (56)
SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). (2020) (55)
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. (2021) (54)
Clinicopathologic Analysis of Pancreatic Adenocarcinoma in African Americans and Caucasians (2003) (54)
Molecular profile of BRCA-mutated biliary tract cancers (2020) (53)
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. (2019) (51)
Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors (2011) (50)
MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy (2010) (50)
A phase II study of carboplatin and paclitaxel in esophageal cancer. (2004) (49)
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. (2002) (49)
Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. (2014) (49)
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. (2018) (48)
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer (2011) (48)
Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer (2019) (48)
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. (2003) (47)
Expert Opinion on Investigational Drugs (1998) (46)
Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. (2007) (44)
Angiogenesis: an update and potential drug approaches (review). (2010) (44)
Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer. (2004) (43)
Defining New Paradigms for the Treatment of Pancreatic Cancer (2011) (42)
Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). (2018) (41)
Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. (2010) (41)
SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas (2007) (41)
A rapid method for determination of acetylation phenotype using dapsone. (1984) (38)
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. (2007) (38)
Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: A Single Institution Experience (2010) (36)
Genetically determined debrisoquine oxidation capacity in bladder cancer. (1984) (35)
Protein Kinase C: A Target for Therapy in Pancreatic Cancer (2008) (35)
Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. (2019) (35)
Ras and exosome signaling. (2019) (35)
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. (2019) (35)
CA19‐9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy (2010) (35)
Developments in the Systemic Therapy of Pancreatic Cancer (2003) (34)
SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. (2017) (34)
Targeting Epidermal Growth Factor Receptor–Related Signaling Pathways in Pancreatic Cancer (2015) (34)
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma (2016) (33)
A Phase II Study of Preoperative Capecitabine and Radiation Therapy in Patients With Rectal Cancer (2007) (32)
Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor (2007) (32)
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities (2018) (32)
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. (2017) (32)
Concurrent inhibition of NF‐κB, cyclooxygenase‐2, and epidermal growth factor receptor leads to greater anti‐tumor activity in pancreatic cancer (2010) (32)
RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. (2012) (32)
Locally advanced pancreatic cancer: where should we go from here? (2011) (31)
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study. (2018) (30)
Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27kip1, p57kip2, and PUMA (2013) (30)
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) (2020) (29)
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (2007) (29)
Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs (1999) (29)
A phase I study of flavopiridol and docetaxel (2006) (29)
Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. (2012) (29)
Polymorphic N-acetylation capacity in lung cancer. (1988) (28)
Potential for protein kinase C inhibitors in cancer therapy. (1995) (28)
Chemoradiotherapy in the Treatment of Regional Pancreatic Carcinoma: A Phase II Study (2003) (28)
SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma. (2019) (28)
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. (1996) (26)
Influence of age, sex and body weight on the dapsone acetylation phenotype. (1987) (26)
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. (2010) (26)
Biochemotherapy for melanoma. (2002) (26)
Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells. (2010) (26)
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer (2007) (26)
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition (2015) (25)
The impact of ARID1A mutation on molecular characteristics in colorectal cancer. (2020) (25)
Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy (2002) (25)
Experience with docetaxel in the treatment of gastric cancer. (2005) (25)
F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. (2016) (25)
A Phase II Study of Carboplatin and Paclitaxel in Adenocarcinoma of Unknown Primary (2005) (25)
Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. (2019) (24)
A review of systemic therapy for advanced pancreatic cancer. (2003) (24)
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1 (2003) (24)
A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). (2018) (24)
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. (1994) (24)
Phase I Study of Bryostatin 1 and Gemcitabine (2006) (24)
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer (2019) (24)
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients (2020) (23)
Improving treatment of pancreatic cancer. (2008) (23)
Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth (2020) (22)
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation (2019) (22)
An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease (2004) (22)
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. (2017) (22)
Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. (2004) (22)
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. (2011) (22)
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells (2005) (21)
Gemcitabine and platinum combinations in pancreatic cancer. (2002) (21)
A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. (1997) (21)
Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. (2017) (21)
A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). (2016) (20)
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. (2020) (20)
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head (2020) (20)
Targeting KRAS in pancreatic cancer: new drugs on the horizon (2021) (20)
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. (2015) (20)
Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma (2019) (20)
Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials (2010) (20)
Treatment of malignant melanoma with interleukin-2. (1997) (20)
Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues. (2003) (20)
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma (2020) (20)
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors (2019) (20)
Phase I study of intravenous 4-hydroxyanisole. (1992) (19)
Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. (1993) (19)
PAR-4 as a possible new target for pancreatic cancer therapy (2010) (19)
Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma. (2022) (19)
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma (1997) (18)
Clinical implication of microRNAs in molecular pathology. (2013) (18)
Characterization of tumor mutation load (TML) in solid tumors. (2017) (18)
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204) (2017) (18)
Angiogenesis: An update and potential drug approaches (Review) (2009) (18)
Gastrointestinal stromal tumor: a review of current and emerging therapies (2021) (18)
Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations (2020) (17)
Accomplishments in 2007 in the treatment of metastatic pancreatic cancer. (2008) (17)
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration (2017) (17)
Secondary cancers after a lung carcinoid primary: a population-based analysis. (2006) (16)
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma (2004) (16)
Protein kinases C isozymes are differentially expressed in human breast carcinomas. (2009) (16)
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU (2005) (16)
Gemcitabine and UFT plus oral calcium folinate: phase I study. (1999) (15)
Novel targets for pancreatic cancer therapy. (2010) (15)
Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma (2009) (15)
Has combined modality therapy improved the outlook in carcinoma of the esophagus? (1994) (15)
SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer. (2015) (14)
Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges (2018) (14)
AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions (2019) (14)
PET scans as a predictive marker of survival in advanced colorectal cancer. (2015) (14)
Molecular variances between rectal and left-sided colon cancers. (2017) (14)
Convulsions and transient cortical blindness after cisplatin. (1991) (14)
Targeting angiogenesis in pancreatic cancer (2008) (14)
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors (2004) (13)
Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model (2001) (13)
APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). (2016) (13)
Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer (2016) (13)
Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma Treated with Yttrium-90 Microsphere Radioembolization (2013) (13)
Targeted therapies for pancreatic cancer. (2008) (13)
LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival (2021) (13)
Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. (2017) (13)
Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy (2005) (12)
Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). (2012) (12)
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. (2014) (12)
A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer (2008) (12)
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. (1994) (12)
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. (2015) (12)
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers (2007) (12)
Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. (2017) (12)
Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study (2008) (12)
A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. (2016) (11)
Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside (2021) (11)
Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6 (2006) (11)
Systemic therapy for advanced pancreatic cancer (2002) (11)
Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies (2020) (11)
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. (2014) (11)
Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer (2004) (11)
Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma (2020) (11)
PreoperativeModified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A 021101 (2019) (11)
A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer. (2017) (10)
APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA). (2014) (10)
Albumin-bound paclitaxel plus gemcitabine after first-line FOLFIRINOX therapy in patients with pancreatic cancer. (2014) (10)
Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors. (2018) (10)
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 (2021) (10)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. (2019) (10)
Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). (2019) (10)
Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs (2021) (10)
Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. (2020) (10)
The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis (2013) (9)
Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. (2019) (9)
Systems biology approaches to pancreatic cancer detection, prevention and treatment. (2014) (9)
Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. (2009) (9)
Biochemotherapy for melanoma (2000) (9)
Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation (2021) (9)
The Role of Cancer Stem Cells and MicroRNAs in the Development and Progression of Pancreatic Cancer (2013) (9)
Pancreatic cancer: the evolving role of systemic therapy (2001) (9)
Clinicopathological analysis of primary epithelial appendiceal neoplasms (2010) (9)
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer (2021) (8)
DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma (2019) (8)
A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. (2012) (8)
A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. (1993) (8)
Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. (2019) (8)
Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA). (2012) (8)
Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl) (2012) (7)
Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001. (2021) (7)
Acetylation and oxidation phenotypes in malignant lymphoma (2004) (7)
Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. (2018) (7)
The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo. (1993) (7)
Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. (2012) (7)
The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers (2004) (7)
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome (2020) (6)
Molecular characterization of squamous cell carcinoma of the anal canal. (2017) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
MDM2 inhibitors for pancreatic cancer therapy. (2010) (6)
Clinical management of long-term cancer survivors. (2008) (6)
Interleukin-2 in the treatment of malignant melanoma. (1998) (6)
Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers. (2019) (6)
Interleukin-2 in cancer (2000) (6)
Effect of cancer chemotherapy on dapsone N-acetylation in man (2004) (6)
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer (2019) (6)
An update on the multimodality of localized rectal cancer. (2016) (6)
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 (2009) (6)
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets (2022) (6)
Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl). (2012) (6)
Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). (2012) (6)
LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC). (2016) (6)
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. (1999) (5)
Molecular Characterization of Appendiceal Goblet Cell Carcinoid (2020) (5)
Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC). (2020) (5)
SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. (2010) (5)
Comparative molecular analyses of colon versus rectal tumors. (2016) (5)
Development of targeted therapies for pancreatic cancer. (2011) (5)
Phase I study of the mitomycin C analogue BMS-181174. (1998) (5)
Inactivation of NFK B by 3 , 3 ¶-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells (2007) (5)
SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy. (2013) (5)
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus (2021) (5)
Evolving standards of care for resected pancreatic cancer. (2017) (5)
Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. (2019) (5)
A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions. (2020) (5)
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation (2004) (5)
Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations. (2019) (4)
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers (2022) (4)
P-185Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT (2015) (4)
Phase I study of the mitomycin C analogue BMY 25067 (1993) (4)
Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC) (2019) (4)
MicroRNAs in Breast Cancer Research: Progress and Promise (2013) (4)
P-286Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study (2016) (4)
A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer (2005) (4)
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer (2021) (4)
Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center (2019) (4)
Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) (2015) (4)
Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC). (2010) (4)
An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2019) (4)
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer (2017) (4)
MicroRNAs in cancer invasion and metastasis (2011) (4)
Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS (2021) (4)
Cytochrome P 450 and Glutathione Transferase Expression in Human Breast Cancer 1 (2003) (4)
Molecular landscape of colorectal cancers harboring R-spondin fusions. (2019) (4)
A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative patients. (2006) (4)
A phase III trial of tumor-treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3. (2021) (3)
Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. (2019) (3)
Abstract 5027: MicroRNA profiling of diagnostic fine needle aspirates of pancreatic cancer preserved as formalin-fixed paraffin-embedded cell blocks (2012) (3)
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers. (1987) (3)
Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy (2004) (3)
Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses (2019) (3)
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). (2011) (3)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. (2019) (3)
Reply to S. Boeck et al (2011) (3)
Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer. (2019) (3)
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question? (2021) (3)
BRCA mutations in pancreatic cancer and progress in their targeting (2021) (3)
Phase II/III study of SM-88 in patients with metastatic pancreatic cancer. (2021) (3)
Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). (2017) (3)
Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma. (2014) (3)
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients (2021) (3)
Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. (2006) (3)
Classification of early-stage colon cancer with Immunoscore®: clinical evidence and case studies. (2021) (2)
A Phase I Study of Gemcitabine and Uracil-Ftorfar (UFT)/Leucovorin (2007) (2)
ASO Visual Abstract: Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers – Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809) (2022) (2)
A phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP) (2005) (2)
Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study. (2016) (2)
Cytochrome P 450 and Glutathione Transferase Expression in Squamous Cell Cancer (2004) (2)
The impact of primary tumor sidedness on survival in early‐onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis (2021) (2)
A phase I safety and pharmacokinetic (PK) study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients (pts) with advanced pancreatic cancer (APC) who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction. (2016) (2)
A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond (2022) (2)
Phase II study of CI-958 in colorectal cancer (1999) (2)
First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues. (2009) (2)
Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer. (2019) (2)
A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer (2006) (2)
Targeting macrophages to treat pancreatic cancer. (2016) (2)
SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis (2020) (2)
Circadian clock gene PER1 mutations in colorectal cancer (CRC). (2018) (2)
Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome. (2016) (2)
Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC). (2017) (2)
Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. (2017) (2)
PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC). (2020) (2)
Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer (2019) (2)
Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505. (2021) (2)
Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. (2020) (2)
Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases. (2016) (1)
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922. (2023) (1)
A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer. (2004) (1)
A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations. (2021) (1)
Clinical outcome of advanced colorectal cancer patients pre- and post-bevacizumab therapy using the SEER database. (2011) (1)
Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes. (2021) (1)
Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon. (2019) (1)
Chemotherapeutic Agents in Human Cancer Cells Genistein Contributes to Increased Apoptosis Induced by B by Soy Isoflavone κ Inactivation of Nuclear Factor Updated (2005) (1)
Systems Biology of Pancreatic Cancer Stem Cells (2014) (1)
nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). (2015) (1)
Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center (2019) (1)
P-272The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC) (2016) (1)
Abstract 234: A novel, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), RP7214, potentiates activity of chemotherapeutics in breast and colorectal cancers (2020) (1)
Systems Biology Approaches in the Design of Effective miRNA-Targeted Therapeutics (2014) (1)
O-005Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma, and impact of molecular profile on outcome (2016) (1)
Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers (2021) (1)
Textbook of Gastrointestinal Oncology (2019) (1)
Activity and safety of carboplatin and paclitaxel followed by capecitabine and radiation as adjuvant therapy for gastric cancer (GC) (2007) (1)
A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period (2008) (1)
Phase I study of anti-CD3 x anti-EGFR–armed activated T-cells for treatment of advanced colorectal or pancreatic cancer. (2015) (1)
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. (2023) (1)
Colorectal cancer: Impact of primary tumor location on genetic alterations. (2017) (1)
A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer. (2006) (1)
A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. (2009) (1)
Targeting B Cells in Pancreatic Adenocarcinoma: Does RESOLVE resolve the question? (2021) (1)
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor. (1999) (1)
Clinical outcome for continuous versus intermittent chemotherapy for unresectable metastatic colorectal cancer: Comparative analysis after first-line therapy. (2018) (1)
Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809) (2023) (1)
Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions. (2020) (1)
CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials. (2011) (1)
Molecular Pathogenesis of Breast Cancer and the Role of MicroRNAs (2014) (1)
Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC). (2018) (1)
The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC). (2022) (1)
Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer (2009) (1)
Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors. (2018) (1)
622PDnab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial (2017) (1)
Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC). (2019) (1)
Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). (2012) (1)
Are we ready for neoadjuvant therapy in potentially resectable pancreatic cancer? (2011) (1)
Erratum: Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells (Cancer Research (August 1, 2005) 65 (6934-6942)) (2005) (1)
Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT) (2015) (1)
Liver-directed therapies for hepatocellular cancer (2007) (1)
Emerging Systemic and Targeted Therapies (2016) (1)
Cardiac toxicity associated with dose and gender in patients undergoing chemoradiation for esophageal carcinoma. (2012) (1)
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy (2022) (1)
Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma (2020) (1)
1567TiP A phase III trial of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3 (2020) (1)
Abstract B38: Clinical translation of nuclear export inhibitor in metastatic pancreatic cancer (2016) (1)
The miR-146a regulates EGFR signaling both in vitro and in a mouse model of pancreatic cancer in vivo (2013) (0)
Systemic Therapy of Pancreatic Cancer: Better Science, Faster Progress. (2015) (0)
A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer 1 (2001) (0)
Evaluation of a novel MDM-2 inhibitor with cisplatin/oxalipatin for the treatment of pancreatic cancer independent of p53 mutational status. (2010) (0)
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. (2023) (0)
Abstract 5420: Multi-targeted approach for inhibiting pancreatic tumor growthin vivoconsistent within vitroresults (2010) (0)
MicroRNA analysis of fine-needle aspirates from pancreatic cancer. (2012) (0)
Pancreatic cancer: why we must be optimistic? (2021) (0)
Mixed photon and neutron radiotherapy given concurrently with chemotherapy in unresectable pancreatic cancer. (2011) (0)
Abstract A021: Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: the phase 3 PANOVA-3 study (2022) (0)
REVIEW miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma (2018) (0)
SO-23 Prognostic impact of microsatellite instability/mismatch repair deficiency on patients with stage III colon cancer and stage IV colorectal cancers: Analysis of 42,984 patients in the National Cancer Database (NCDB) (2020) (0)
454P CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value (2021) (0)
Poor Effectiveness of Ultrasound Surveillance Prior to Diagnosis of HCC in a Predominately African American Population (2017) (0)
Comparative analysis of the effect of bevacizumab maintenance regimens after first-line chemotherapy in patients with metastatic colorectal cancer (MCRC): A single institution experience. (2017) (0)
The outcome of patients with advanced hepatocellular carcinoma (HCC) in pre- and post-sorafenib eras using the SEER database. (2013) (0)
A guide to tumor assessment methodologies in cancer drug discovery (2019) (0)
Promising SINEs in the Treatment of Pancreatic Cancer (2015) (0)
A guide to tumor assessment methodologies in cancer drug discovery (2019) (0)
Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival. (2019) (0)
Preliminary Results of a Phase 1 Study of Hyperfractionated Low-Dose Radiation Therapy (RT) as a Chemotherapy Sensitizer in Combination With Gemcitabine (G) and Erlotinib (E) in Advanced Pancreatic Cancer (2013) (0)
Retraction to: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines (Cancer, 10.1002/cncr.24250) (2016) (0)
Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809. (2021) (0)
730PInterim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC) (2017) (0)
Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107. (2023) (0)
Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors. (2012) (0)
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers (2023) (0)
Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas. (2018) (0)
Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results. (2022) (0)
Preferences and Attitudes of Cardiologists in Management of Patients with Cancer (2022) (0)
Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1. (2016) (0)
Issue information (2014) (0)
Abstract 4535: MDM2 inhibitor MI-319 in combination with cisplatin/oxaliplatin is an effective treatment for pancreatic cancer independent of p53 function (2010) (0)
APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC): 232 (2014) (0)
Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC. (2020) (0)
Erratum: Breast cancer in women with human immunodeficiency virus infection: Implications for diagnosis and therapy - Five case reports and a review of literature (Breast Cancer Research and Treatment (2002) 76 (111-116)) (2004) (0)
P-184nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study (2015) (0)
Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC). (2018) (0)
Phase I Study of Bryostatin1and Gemcitabine (2006) (0)
Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer. (2018) (0)
Radiation induced cardiac changes following treatment for left-sided breast cancer (2000) (0)
PCN116 Using the Modified RAND/UCLA Delphi Process to Produce Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors (2012) (0)
Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancers (2015) (0)
Molecular characterization of appendiceal goblet cell carcinoid. (2020) (0)
The Role of microRNAs in Tumor Progression and Therapy (2013) (0)
Abstract 1122: Novel targets for therapy resistant pancreatic neuroendocrine tumors (2021) (0)
A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer (2008) (0)
Abstract PO-051: PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (2021) (0)
Abstract 682: Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance]) (2022) (0)
Feasibility of a multi-institutional liver cancer registry. (2006) (0)
PCN117 An Expert Panel Consensus on Medical Treatment of Non-Midgut Unresectable Neuroendocrine Tumors (2012) (0)
Abstract 464: Novel role of xpo1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis (2017) (0)
Abstract 5589: Molecular diagnostic, prognostic and therapeutic role of mir-221 in pancreatic cancer (2014) (0)
Current and Emerging Therapies in Pancreatic Cancer (2018) (0)
Abstract 4368: PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors (2018) (0)
Gastrointestinal malignancies in the elderly (1995) (0)
PET scan as a prognostic marker in advanced colorectal cancer. (2014) (0)
1053 Hepatocellular Carcinoma (HCC) Diagnosis, Treatment and Outcome in a Primarily African American Population (2019) (0)
Abstract 154: miRNAs in plasma of pancreatic cancer patients (2011) (0)
CA 19–9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy (2005) (0)
A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer (2004) (0)
Abstract IA010: Meeting the challenge of pancreatic cancer (2022) (0)
Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo). (2017) (0)
Abstract LB299: Identification of key regulators for nuclear protein export inhibitor and chemotherapy combination in pancreatic cancer using spatial genomics approach (2023) (0)
Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile. (2018) (0)
A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer. (2017) (0)
Selected ongoing clinical trials evaluating cytotoxic therapy in pancreatic cancer Agent Mechanism of action Phase Combination therapy (2011) (0)
Abstract 1873: The role of p21-activated kinase 4 (PAK4) in cancer stemness and epithelial-to-mesenchymal transition (2016) (0)
Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. (2007) (0)
Abstract 3069: Efficacy of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor, in preclinical models of gastrointestinal cancers (2019) (0)
Advancements in the treatment of mCRC : Improvements in the management of liver metastases (2008) (0)
Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma (HCC) Treated with YTTRIUM-90 Microsphere Radioembolization (SIRT) (2012) (0)
Characteristics of colorectal cancer in patients younger than 40 years compared to older patients. (2013) (0)
Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers. (2021) (0)
How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy (2019) (0)
Role of Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma Associated Cachexia. (2022) (0)
1075 : A Phase II Trial of Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Resectable or Unresectable Non-Metastatic Pancreatic Cancer (2006) (0)
18f-fluorodeoxyglucose-positron emission tomography (FDG-PET) as a predictive biomarker in metastatic colorectal cancer (mCRC). (2010) (0)
Systems and Network Biology in MicroRNA based Personalized Medicine (2013) (0)
Abstract CT234: PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma (2022) (0)
Molecular landscape of gastric cancer (GC) harboring mutations of histone methyltransferases. (2020) (0)
Epigenetic Silencing of EzH2 By RNA Interference As A Potential Therapy For Pancreatic Adenocarcinoma (2011) (0)
Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program. (2017) (0)
Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis (2023) (0)
746TiPAPACT: A PHASE III TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR RESECTED PANCREATIC CANCER (PC). (2014) (0)
Neoadjuvant therapy for pancreatic cancer (2023) (0)
Reply to A. Aref et al and E. Ben-Josef et al (2012) (0)
Abstract 4910: Unveiling the role of network and systems biology in pancreatic cancer drug discovery (2011) (0)
Abstract 3476: Evaluable antitumor activity in metastatic pancreatic adenocarcinoma with specific inhibitor of nuclear export based treatment (2019) (0)
Two patients with elevated alpha-fetoprotein levels and liver lesions in the absence of hepatocellular carcinoma (2009) (0)
Abstract 2383: Mir-7974: An oncogenic miRNA that perpetuates gastric cancer (2021) (0)
Understanding practices and gaps in multidisciplinary hepatocellular carcinoma (HCC) care within the community oncology setting. (2019) (0)
A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types. (2021) (0)
PET SUVmax as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy in Patients With Carcinoma of the Esophagus (2014) (0)
Uncommon Cancers of the Pancreas (2017) (0)
P-186International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT (2015) (0)
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192. (2023) (0)
Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study. (2023) (0)
Pitfalls in Clinical Trials and Future Directions (2008) (0)
Novel Targeted Treatment Approaches in Pancreatic Cancer (2019) (0)
Abstract B22: Re-expression of miR-200 by natural agents regulates the expression of PTEN and MT1-MMP in pancreatic cancer (2012) (0)
Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns. (2020) (0)
Molecular profiling of pancreatic neuroendocrine neoplasms (panNENs): A single-institution experience. (2021) (0)
Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes. (2019) (0)
Retraction to: Response to dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor (Cancer, 10.1002/cncr.23100) (2016) (0)
Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 319(2) (2012) 173-181]. (2018) (0)
Profiling for microsatellite instability (MSI) and mismatch repair (MMR) among patients with colon cancer in real world settings. (2018) (0)
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations. (2023) (0)
Abstract 209: Zinc is essential for the efficacy of p53 reactivating drugs (2011) (0)
Treatment of Advanced Pancreatic Carcinoma (2019) (0)
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). (2022) (0)
Treatment of Rectal Cancer (2019) (0)
High linear energy transfer (LET) radiation therapy in recurrent, metastatic, or unresectable rectal adenocarcinoma. (2011) (0)
Novel Agents in Pancreatic Cancer (2017) (0)
Pancreatic Fine Needle Aspirate miRNA miR-221 for Early Diagnosis, Prognosis and Targeted Therapy for Precision Medicine (2014) (0)
A new combination for advanced multiple myeloma (2011) (0)
Combining sorafenib with chemoembolization for hepatocellular cancer (2011) (0)
HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (2018) (0)
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma. (2023) (0)
Molecular characterization of early vs. late onset gastroesophageal cancers. (2017) (0)
Carcinoma of the Esophagus April (2017) (0)
Treatment of Advanced Pancreatic Cancer (2015) (0)
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma. (2021) (0)
Radiosensitization with capecitabine in gastrointestinal malignancies (2001) (0)
PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma. (2022) (0)
Time for better presentation and analysis of adverse events (2016) (0)
A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer. (2013) (0)
A molecular medicine resource (2006) (0)
Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (2018) (0)
Original Article Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through (2013) (0)
Comparative molecular analyses of pancreatic cancer (PC): Younger vs. older patients (pts) (2016) (0)
Targeting Rho, Rac, CDC42 GTPase Effector p21 Activated Kinases in Mutant K-Ras-Driven Cancer (2017) (0)
Gallbladder Cancer: Current and Emerging Therapies (2019) (0)
Retraction: Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer (2018) (0)
Prognostic factors for metastatic colorectal cancer with and without bevacizumab therapy. (2012) (0)
Aberrant transcription factors in the cancers of the pancreas. (2022) (0)
Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. (2007) (0)
Abstract PO-024: Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy (2021) (0)
18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). (2016) (0)
Comparison of fluoropyrimidine based (FP)and taxane based platinum doublets (TP) in frontline treatment of patients with metastatic gastroesophageal adenocarcinomas (mGEAC): A retrospective analysis. (2017) (0)
Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience. (2018) (0)
13.27 Radiation induced changes in myocardial blood flow following treatment for left-sided breast cancer (2001) (0)
Abstract 1231: Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin, or irinotecan (2022) (0)
Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philip Agop Philip?

Philip Agop Philip is affiliated with the following schools:

University of British Columbia
University of Michigan
Wayne State University
University of Southern California
University of Turin
Duke University